ArticleJAMA internal medicine2018
Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease.
Article in JAMA internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- ACC/AHA/ASE/HFSA/HRS/SCAI/SCCT/SCMR 2025 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy, and Pacing.Journal of the American College of Cardiology · 2025Guideline
- Frailty, Implantable Cardioverter Defibrillators, and Mortality: a Systematic Review.Journal of general internal medicine · 2019Pooled it
- Impact of underlying kidney disease on the outcomes of cardiac implantable electronic devices in patients with heart failure.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Article
- Artificial Intelligence in Cardiovascular Medicine: A Giant Step in Personalized Medicine?Journal of personalized medicine · 2026Review
- Nonatherosclerotic Cardiovascular Disease in Chronic Kidney Disease.Cardiology clinics · 2025Review
- Heart failure with reduced ejection fraction and chronic kidney disease: a focus on therapies and interventions.Heart failure reviews · 2025Review
- Ventricular arrhythmias in the context of chronic kidney disease and electrolyte imbalance.Herzschrittmachertherapie & Elektrophysiologie · 2024Review
- Management of patients with heart failure and chronic kidney disease.Heart failure reviews · 2024Review
- Cardiac Device Therapy in Patients with Chronic Kidney Disease: An Update.Journal of clinical medicine · 2024Review
- Comparison of infection and complication rates associated with transvenous vs. subcutaneous defibrillators in patients with stage 4 chronic kidney disease: a multicenter long-term retrospective follow-up.Frontiers in cardiovascular medicine · 2024Article
- Emerging Preventive Strategies in Chronic Kidney Disease: Recent Evidence and Gaps in Knowledge.Current atherosclerosis reports · 2023Review
- Elevated serum albumin-to-creatinine ratio as a protective factor on outcomes after heart transplantation.Frontiers in cardiovascular medicine · 2023Article
- Can the Norton Scale Score Be Used as an Adjunct Tool for Implantable Defibrillator Patient Selection? A Retrospective Single-Center Cohort Study.Journal of clinical medicine · 2022Article
- Quality of observational studies of clinical interventions: a meta-epidemiological review.BMC medical research methodology · 2022Review
- The subcutaneous implantable cardioverter-defibrillator should be reserved for niche indications.Heart rhythm O2 · 2022Article
- Implantable cardioverter-defibrillator placement among patients with left ventricular ejection fraction ≤35 % at least 40 days after acute myocardial infarction.American heart journal plus : cardiology research and practice · 2022Article
- Timing of AKI after urgent percutaneous coronary intervention and clinical outcomes: a high-dimensional propensity score analysis.BMC nephrology · 2021Article
- Cumulative Adherence to Secondary Prevention Guidelines and Mortality After Acute Myocardial Infarction.Journal of the American Heart Association · 2020Article
- Updates in the management of heart failure for the chronic kidney disease patient.Current opinion in nephrology and hypertension · 2019Review
- Rationale and design of the EU-CERT-ICD prospective study: comparative effectiveness of prophylactic ICD implantation.ESC heart failure · 2019Observational
Corrections and comments
- Commented on by
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Chronic kidney disease (CKD) is common in adults with heart failure and is associated with an increased risk of sudden cardiac death. Randomized trials of participants without CKD have demonstrated that implantable cardioverter defibrillators (ICDs) decrease the risk of arrhythmic death in selected patients with reduced left ventricular ejection fraction (LVEF) heart failure. However, whether ICDs improve clinical outcomes in patients with CKD is not well elucidated. Objective: To examine the association of primary prevention ICDs with risk of death and hospitalization in a community-based population of potentially ICD-eligible patients who had heart failure with reduced LVEF and CKD. Design, Settings, and Participants: This noninterventional cohort study included adults with heart failure and an LVEF of 40% or less and measures of serum creatinine levels available from January 1, 2005, through December 31, 2012, who were enrolled in 4 Kaiser Permanente health care delivery systems. Chronic kidney disease was defined as an estimated glomerular filtration rate of less than 60 mL/min/1.73 m2. Patients who received and did not receive an ICD were matched (1:3) on CKD status, age, and high-dimensional propensity score to receive an ICD. Follow-up was completed on December 31, 2013. Data were analyzed from 2015 to 2017. Exposures: Placement of an ICD. Main Outcomes and Measures: All-cause death, hospitalizations due to heart failure, and any-cause hospitalizations. Results: A total of 5877 matched eligible adults with CKD (1556 with an ICD and 4321 without an ICD) were identified (4049 men [68.9%] and 1828 women [31.1%]; mean [SD] age, 72.9 [8.2] years). In models adjusted for demographics, comorbidity, and cardiovascular medication use, no difference was found in all-cause mortality between patients with CKD in the ICD vs non-ICD groups (adjusted hazard ratio, 0.96; 95% CI, 0.87-1.06). However, ICD placement was associated with increased risk of subsequent hospitalization due to heart failure (adjusted relative risk, 1.49; 95% CI, 1.33-1.60) and any-cause hospitalization (adjusted relative risk, 1.25; 95% CI, 1.20-1.30) among patients with CKD. Conclusions and Relevance: In a large, contemporary, noninterventional study of community-based patients with heart failure and CKD, ICD placement was not significantly associated with improved survival but was associated with increased risk for subsequent hospitalization due to heart failure and all-cause hospitalization. The potential risks and benefits of ICDs should be carefully considered in patients with heart failure and CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.